Eurofins MWG Operon specializes in advanced DNA and RNA synthesis technologies, offering a range of products and services that cater to the needs of the scientific community. Their proprietary synthesis technology enables the rapid production of high-quality oligonucleotides, including primers and probes, which are essential for various applications such as PCR, RT-PCR, and sequencing. The company emphasizes the speed and efficiency of its oligonucleotide synthesis, claiming to provide the fastest turnaround times in the industry. Additionally, Eurofins MWG Operon supports a wide array of modifications for both DNA and RNA, allowing for tailored solutions that meet specific research requirements.

In the realm of sequencing, Eurofins MWG Operon offers both Sanger and Nanopore sequencing services, which are designed to deliver accurate and timely results for gene therapy and other applications. Their sequencing technologies are complemented by a commitment to quality assurance, adhering to GMP, GLP, and ISO standards. The company also focuses on custom solutions, ensuring that their products integrate seamlessly into clients' workflows. By leveraging their expertise in molecular diagnostics and genomics, Eurofins MWG Operon plays a crucial role in advancing research across various fields, including agroscience, clinical diagnostics, and infectious disease detection.

United States

Eurofins Genomics LLC is a member of the Eurofins Group with major offices and production facilities in the United States, Europe, and Asia, is an international provider of DNA sequencing services, DNA synthesis products, and bioinformatic services for academic and industrial research. The company’s strengths are its strong customer orientation, fast service and high quality products including a series of advanced oligonucleotide design tools.

Eurofins MWG Operon

Company Details